Results 231 to 240 of about 1,058,605 (377)

An Off‐the‐Shelf Artificial Proregenerative Macrophage for Pressure Ulcer Treatment

open access: yesAdvanced Science, EarlyView.
Artificial macrophages (artM) by encapsulating M2 lysates into biodegradable PLGA microspheres and coated with macrophage membrane, are engineered as new therapeutics against skin pressure ulcer. In mouse models, the artM exhibited robust tissue repair through cell recruitment and microenvironment modulation, showing great therapeutic potential for ...
Qi Su   +12 more
wiley   +1 more source

Trifunctional Sialylation‐Based SF‐ZIF@NA Hydrogel for Selective Osteoclast Inhibition and Enhanced Bone‐Vessel Regeneration in Osteoporotic Bone Defects

open access: yesAdvanced Science, EarlyView.
This study introduces the SF‐ZIF@NA hydrogel system for osteoporotic bone defect treatment. The hydrogel inhibits osteoclast fusion by removing sialic acid and preserves the anabolic function of precursor osteoclasts (pOCs). It also releases Zn2⁺ in acidic conditions, promoting osteogenesis and angiogenesis.
Zhengrong Chen   +13 more
wiley   +1 more source

Exercise without Weight Loss Prevents Seasonal Decline in Vitamin D Metabolites: The VitaDEx Randomized Controlled Trial

open access: yesAdvanced Science, EarlyView.
In people with overweight or obesity, regular exercise even without weight loss or vitamin D supplementation completely prevents the usual winter decline in the vitamin D metabolite that maintains health at a cellular level, 1,25(OH)2D3, and ameliorates the decline in the vitamin D status marker 25(OH)D.
Oliver J. Perkin   +11 more
wiley   +1 more source

S‐ketamine Alleviates Neuroinflammation and Attenuates Lipopolysaccharide‐Induced Depression Via Targeting SIRT2

open access: yesAdvanced Science, EarlyView.
S‐ketamine binds directly to SIRT2, facilitating its interaction with NF‐κB p65. This interaction reduces the acetylation of NF‐κB p65 and inhibits its activation, thereby exerting anti‐inflammatory and antidepressant effects. Created by BioRender.
Cong Lin   +7 more
wiley   +1 more source

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

open access: yesAmerican Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy